Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

ABSTRACT: This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer

DISEASE(S): Braf Mutado Cáncer Colorrectal Metastásico,Braf Mutant Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2134540 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR